Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics

Cancer Immunology Immunotherapy

Volumn 44, Issue 1, 1997, Pages 55-63

  Roth, Wilfried ^a   Fontana, Adriano ^b   Trepel, Martin ^a   Reed, John C ^c   Dichgans, Johannes ^a   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BURNHAM INSTITUTE   (United States)

Author keywords

apoptosis; CD95 (Fas APO 1); chemotherapy; malignant glioma; synergy

Indexed keywords

CARMUSTINE; CD45 ANTIGEN; CD95 LIGAND; CYCLOHEXIMIDE; CYTARABINE; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PROTEIN P53; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL LINE; CYTOTOXICITY; GLIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030896574     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050355     Document Type: Article

References (41)

1. Alderson LM, Castleberg RI, Harsh GR IV, Louis DN, Henson JW (1995) Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999
2. Alexander RB, Nelson WG, Coffey DS (1987) Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 47: 2403
3. Bellgrau D, Gold D, Selawry H, Moore J, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630
4. Bögler O, Huang HJS, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Glia 15: 308
5. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405
6. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R (1994) Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 180: 1547
7. Deng G, Podack ER (1993) Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA 90: 2189
8. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585
9. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539
10. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Müller C, Tschopp J (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335
11. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189
12. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T, Baier G, Baier-Bitterlich G, Byrd C, Lang F, Kolesnick R, Altman A, Green DR (1995) FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2: 341
13. Karasuyama H, Melchers F (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 18: 97
14. Kerr JFR, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013
15. Krosnick JA, Mulé JJ, McIntosh JK, Rosenberg SA (1989) Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 49: 3729
16. Lesser GJ, Grossman S (1994) The chemotherapy of high-grade astrocytomas. Semin Oncol 21: 220
17. Louis DN, Von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestier OD, Thor AD, Seizinger BR (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31
18. Martin SJ, Green DR (1995) Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol/Hematol 18: 137
19. Morimoto H, Yonehara S, Bonavida B (1993) Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 53: 2591
20. Nagata S, Golstein P (1995) The fas death factor. Science 267: 1449
21. Ogasawara J, Watanabe-Funkunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806
22. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1
23. Reed JC (1995) Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451
24. Regenass U, Müller M, Curschellas E, Matter E (1987) Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 39: 266
25. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A (1995) Loco-regional Fas/ APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25: 2253
26. Safrit JT, Bonavida B (1992) Sensitivity of resistant human tumor cell lines to tumor necrosis factor and Adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res 52: 6630
27. Suda T, Takahashi T, Golstein P, Nagata S (1994) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169
28. Tachibana O, Nakazawa H, Lampe I, Watanabe K, Kleihues P, Ohgaki H (1995) Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528
29. Thompson CB (1995) Apoptosis in the pathogenesis of treatment and disease. Science 27: 1456
30. Ullrich SJ, Mercer WE, Appella E (1992) Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 7: 1635
31. Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte P, Russo P (1993) Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer 29A: 1157
32. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJS, Friedmann T, De Tribolet N, Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649
33. Webb JL (1963) Effect of more than one inhibitor. In: Enzyme and metabolic inhibitors, vol. 1. Academic Press, New York, pp 66, 487
34. Weller M, Fontana A (1995) The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21: 128
35. 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24: 1293
36. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954
37. Weller M, Frei K, Malipiero U, Groscurth P, Yonekawa Y, Krammer P, Fontana A (1995) Fas/APO-1-mediated apoptosis of human malignant glioma. Neurology 45 (Suppl 4): 859S
38. Weller M, Malipiero UV, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633
39. 2: modulation by the phosphatase inhibitors, okadaic acid and calyculin A. Exp Cell Res 221: 395
40. Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A (1995) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936
41. Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747